Tearsheet
Investment Highlights Market Valuation Price Chart Business Description Interactive Breakdown Latest Trefis Analyses Better Bets vs. HAE Recent Active Movers More From Trefis Peer Financials Peer Growth & Margins Peer Valuation Peer Returns Peer Analyses FDIC Bank Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Insider Activity Industry Resource Links External Quote Links

Haemonetics (HAE)

Market Price (9/17/2025): $51.01 | Market Cap: $2.5 Bil
Sector: Health Care | Industry: Health Care Supplies

Haemonetics (HAE)

Market Price (9/17/2025): $51.01
Market Cap: $2.5 Bil
Sector: Health Care
Industry: Health Care Supplies

Investment Highlights

0 Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 6.7%, FCF Yield is 7.7%		 Weak multi-year price returns
2Y Excs Rtn is -91%, 3Y Excs Rtn is -96%		 Weak revenue growth
Rev Chg QQuarterly Revenue Change % is -4.4%
1 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 17%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 14%		  
2 Low stock price volatility
Vol 12M is 44%		  
0 Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 6.7%, FCF Yield is 7.7%
1 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 17%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 14%
2 Low stock price volatility
Vol 12M is 44%
3 Weak multi-year price returns
2Y Excs Rtn is -91%, 3Y Excs Rtn is -96%
4 Weak revenue growth
Rev Chg QQuarterly Revenue Change % is -4.4%

Market Valuation

 9/17/25202420232022
Share Price CYE$51.01$78.08$85.51$78.65
Market Cap CYE ($ Bil)2.53.94.34.0
Total Debt ($ Bil)1.21.20.80.8
Total Cash ($ Bil)0.30.30.20.3
Enterprise Value ($ Bil)3.45.15.14.8
Valuation Ratios    
P/S TTM1.82.93.33.4
P/EBIT TTM10.417.726.325.6
P/E TTM15.023.436.934.6
Sector Ratios    
P/S TTM (Sector)3.73.64.14.5
P/EBIT TTM (Sector)-1.6-1.3-1.4-1.3
P/E TTM (Sector)-1.8-1.5-1.5-1.3
 9/17/252024
Share Price CYE$51.01$78.08
Market Cap CYE ($ Bil)2.53.9
Total Debt ($ Bil)1.21.2
Total Cash ($ Bil)0.30.3
Enterprise Value ($ Bil)3.45.1
Valuation Ratios  
P/S TTM1.82.9
P/EBIT TTM10.417.7
P/E TTM15.023.4
Sector Ratios  
P/S TTM (Sector)3.73.6
P/EBIT TTM (Sector)-1.6-1.3
P/E TTM (Sector)-1.8-1.5

Market Cap Chart

Business Description

Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. Show more

Price Returns Compared

Expand for Detailed View

 202020212022202320242025Total [1]
Returns
HAE Return3%-55%48%9%-9%-35%-55%
Peers Return61%25%-27%5%-17%-16%6%
S&P 500 Return16%27%-19%24%23%12%104%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: MMSI, CNMD, STAA, IART, WST. See HAE Returns vs. Peers.
[3] 2025 data is for the year up to 9/16/2025 (YTD)

Better Bets than Haemonetics (HAE)

 HAEBetter Performance than HAE
MetricValueIndustry (Health Care Supplies)
Rev Chg LTM0.9%WST (2.9%), COO (6.4%), MMSI (8.2%), LNTH (5.7%), ICUI (3.0%)
Rev Chg 3Y Avg9.7%LNTH (34.3%), ICUI (10.7%), NEOG (21.7%)
Op Mgn LTM16.0%WST (21.0%), COO (18.3%), ALGN (16.1%), LNTH (28.9%)
CFO/Rev LTM16.8%WST (22.9%), COO (20.2%), ALGN (18.4%), LNTH (34.7%), BLFS (20.3%)
FCF/Rev LTM14.1%ALGN (15.9%), LNTH (31.1%), BLFS (15.0%)
Total Yield6.7%LNTH (7.6%)
 HAEBetter Performance than HAE
MetricValueAll Other Sectors
Rev Chg LTM0.9%NVDA (71.6%), MSFT (14.9%), AAPL (6.0%), GOOGL (13.1%), AMZN (10.9%)
Rev Chg 3Y Avg9.7%NVDA (92.0%), MSFT (12.5%), GOOGL (10.2%), AMZN (11.3%), META (13.0%)
Op Mgn LTM16.0%NVDA (58.1%), MSFT (45.6%), AAPL (31.9%), GOOGL (32.7%), META (42.9%)
CFO/Rev LTM16.8%NVDA (46.6%), MSFT (48.3%), AAPL (26.6%), GOOGL (36.0%), AMZN (18.1%)
FCF/Rev LTM14.1%NVDA (43.6%), MSFT (25.4%), AAPL (23.5%), GOOGL (18.0%), META (30.7%)
Total Yield6.7%XOM (9.7%), BAC (7.2%), BABA (38.9%), KO (7.2%), CVX (9.3%)

Latest Trefis Analyses

TitleTopicDate
0DASHBOARDS  
1Haemonetics Earnings Notes  
2Is The 29.8% Decline In Haemonetics (HAE) Stock A Dip Buying Opportunity?Actionable 
3Is The 27.6% Decline In Haemonetics (HAE) Stock A Dip Buying Opportunity?Actionable 
4Is The 28.6% Decline In Haemonetics (HAE) Stock A Dip Buying Opportunity?Actionable 
5HAE's 27% Decline in a Month Brings Valuations Into Focus - Is JNJ a Better Deal?Counter-Intuitive Comparisons 
6As HAE Falls 27% in a Month, LNTH's Story Stands OutCounter-Intuitive Comparisons 
7Is The 29.6% Decline In Haemonetics (HAE) Stock A Dip Buying Opportunity?Actionable 
8How Does HAE Stack Up Against Its Peers?Peer Comparison 
9Day 6 of Loss Streak for Haemonetics Stock with -32% Return (vs. -33% YTD) [8/12/2025]Notification 
10Better Bet Than HAE Stock: Pay Less Than Haemonetics To Get More From CCL, FTI   
11ARTICLES  
12Stocks Trading At 52-Week Low September 13th, 2025
13Down 30%, Is HAE Stock A Buy Now? September 2nd, 2025
14Better Bet Than Align Technology Stock: Pay Less To Get More From HAE, AVNS August 26th, 2025
15HAE Stock Down 28%, Is It Time To Buy The Dip? August 26th, 2025
16Better Bet Than QuidelOrtho Stock: Pay Less To Get More From HAE, AVNS August 21st, 2025
Title
0DASHBOARDS
1Stocks Trading At 52-Week Low
2Down 30%, Is HAE Stock A Buy Now?
3Better Bet Than Align Technology Stock: Pay Less To Get More From HAE, AVNS
4HAE Stock Down 28%, Is It Time To Buy The Dip?
5Better Bet Than QuidelOrtho Stock: Pay Less To Get More From HAE, AVNS
6ARTICLES
7Haemonetics Earnings Notes
8Is The 29.8% Decline In Haemonetics (HAE) Stock A Dip Buying Opportunity?
9Is The 27.6% Decline In Haemonetics (HAE) Stock A Dip Buying Opportunity?
10Is The 28.6% Decline In Haemonetics (HAE) Stock A Dip Buying Opportunity?
11HAE's 27% Decline in a Month Brings Valuations Into Focus - Is JNJ a Better Deal?
12As HAE Falls 27% in a Month, LNTH's Story Stands Out
13Is The 29.6% Decline In Haemonetics (HAE) Stock A Dip Buying Opportunity?
14How Does HAE Stack Up Against Its Peers?
15Day 6 of Loss Streak for Haemonetics Stock with -32% Return (vs. -33% YTD) [8/12/2025]
16Better Bet Than HAE Stock: Pay Less Than Haemonetics To Get More From CCL, FTI 

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1BDSXBiodesix1313.2%-78.6%
2CLSDClearside Biomedical954.0%-74.9%
3SDOTSadot624.1%-79.4%
4WLDSWearable Devices498.0%-30.0%
5CHEKCheck-Cap285.6%154.6%
6ATCHAtlasClear275.9%-91.0%
7HSDTHelius Medical Technologies262.5%-95.6%
8OPIOffice Properties Income Trust261.7%-13.4%
9FGIFGI Industries156.8%145.2%
10AIREReAlpha Tech154.0%-56.1%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1NAKAKindly MD-81.4% 
2ATYRaTyr Pharma-79.7%-70.2%
3LGCLLucas GC-73.6%-77.1%
4EPSMEpsium Enterprise-70.1% 
5BNGOBionano Genomics-59.4%-89.7%
6FAASDigiAsia-58.5%-87.2%
7QMMMQMMM-57.5%6775.0%
8VCIGVCI Global-56.9%-99.1%
9YYGHYY-56.6%-78.5%
10XAGELongevity Health-55.5%-86.1%

1 Month Top Gainers

#TickerCompany1M RtnYTD Rtn
1PMIPicard Medical11963.5%11963.5%
2GIBOGIBO9734.4% 
3CHSNChanson International7565.0%-99.3%
4LNZALanzaTech Global7287.5%-86.0%
5QMMMQMMM3031.7%6775.0%
6OESXOrion Energy Systems1497.9%22.9%
7CURXCuranex Pharmaceuticals1401.6%1401.6%
8ENTOEntero Therapeutics565.6%117.6%
9PTNMPitanium553.2% 
10WLDSWearable Devices449.5%-30.0%

1 Month Top Losers

#TickerCompany1M RtnYTD Rtn
1CJETChijet Motor-92.2%-95.0%
2STFSStar Fashion Culture-92.2%-97.8%
3ELPWElong Power-91.6%-76.7%
4NXTTNext Technology-89.6%-95.1%
5NAKAKindly MD-89.0% 
6BINIBollinger Innovations-88.9%-100.0%
7JEM707 Cayman-88.4%-98.2%
8YAASYouxin Technology-82.5%-98.3%
9NEONNeonode-82.0%-50.2%
10NVNOenVVeno Medical-81.5%-69.8%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1BDSXBiodesix1313.2%-78.6%
2CLSDClearside Biomedical954.0%-74.9%
3SDOTSadot624.1%-79.4%
4WLDSWearable Devices498.0%-30.0%
5CHEKCheck-Cap285.6%154.6%
6ATCHAtlasClear275.9%-91.0%
7HSDTHelius Medical Technologies262.5%-95.6%
8OPIOffice Properties Income Trust261.7%-13.4%
9FGIFGI Industries156.8%145.2%
10AIREReAlpha Tech154.0%-56.1%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1NAKAKindly MD-81.4% 
2ATYRaTyr Pharma-79.7%-70.2%
3LGCLLucas GC-73.6%-77.1%
4EPSMEpsium Enterprise-70.1% 
5BNGOBionano Genomics-59.4%-89.7%
6FAASDigiAsia-58.5%-87.2%
7QMMMQMMM-57.5%6775.0%
8VCIGVCI Global-56.9%-99.1%
9YYGHYY-56.6%-78.5%
10XAGELongevity Health-55.5%-86.1%

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Haemonetics

Financials

HAEMMSICNMDSTAAIARTWSTMedian
NameHaemonet.Merit Me.Conmed Staar Su.Integra .West Pha. 
Mkt Price51.0282.6952.7427.2314.83258.3551.88
Mkt Cap2.54.91.61.31.118.72.0
Rev LTM1,3461,3881,3162241,6242,9601,367
Op Inc LTM215162181-829622172
FCF LTM189178165-44-25344171
FCF 3Y Avg128125104-1078366115
CFO LTM227225179-29102677202
CFO 3Y Avg2041701228159712165

Growth & Margins

HAEMMSICNMDSTAAIARTWSTMedian
NameHaemonet.Merit Me.Conmed Staar Su.Integra .West Pha. 
Rev Chg LTM0.9%8.2%4.3%-32.6%6.2%2.9%3.6%
Rev Chg 3Y Avg9.7%8.0%8.9%-2.3%1.4%0.4%4.7%
Rev Chg Q-4.4%9.8%2.9%-55.2%3.7%9.2%3.3%
QoQ Delta Rev Chg LTM-1.1%2.3%0.7%-19.6%0.9%2.2%0.8%
Op Mgn LTM16.0%11.7%13.8%-36.4%0.6%21.0%12.7%
Op Mgn 3Y Avg14.2%10.5%10.2%-6.7%6.8%22.2%10.4%
QoQ Delta Op Mgn LTM1.2%0.2%-1.6%-20.2%-1.2%0.5%-0.5%
CFO/Rev LTM16.8%16.2%13.6%-12.7%6.3%22.9%14.9%
CFO/Rev 3Y Avg15.8%13.1%9.6%1.2%10.2%24.6%11.6%
FCF/Rev LTM14.1%12.8%12.5%-19.5%-1.6%11.6%12.1%
FCF/Rev 3Y Avg9.8%9.5%8.1%-5.2%5.1%12.6%8.8%

Valuation

HAEMMSICNMDSTAAIARTWSTMedian
NameHaemonet.Merit Me.Conmed Staar Su.Integra .West Pha. 
Mkt Cap2.54.91.61.31.118.72.0
P/S1.83.51.26.00.76.32.7
P/EBIT10.426.69.0-16.534.631.218.5
P/E15.039.813.8-14.2-39.238.214.4
P/CFO10.821.69.1-47.311.127.611.0
Total Yield6.7%2.5%8.8%-7.1%-2.6%2.8%2.6%
Dividend Yield0.0%0.0%1.5%0.0%0.0%0.2%0.0%
FCF Yield 3Y Avg3.3%2.4%5.7%-1.6%2.0%1.7%2.2%
D/E0.50.20.50.01.80.00.3
Net D/E0.40.10.5-0.11.5-0.00.2

Returns

HAEMMSICNMDSTAAIARTWSTMedian
NameHaemonet.Merit Me.Conmed Staar Su.Integra .West Pha. 
1M Rtn-5.1%-3.3%-0.3%-4.0%4.5%4.9%-1.8%
3M Rtn-26.1%-11.0%1.3%63.7%22.1%18.6%10.0%
6M Rtn-21.1%-17.3%-12.3%49.0%-34.4%10.4%-14.8%
12M Rtn-33.5%-17.0%-28.7%-13.2%-14.4%-12.7%-15.7%
3Y Rtn-33.5%42.6%-40.5%-68.1%-67.4%-2.9%-37.0%
1M Excs Rtn-7.5%-5.7%-2.8%-6.5%2.1%2.5%-4.3%
3M Excs Rtn-36.6%-21.3%-10.3%50.8%10.2%5.8%-2.3%
6M Excs Rtn-37.7%-34.3%-29.9%38.2%-52.3%-4.6%-32.1%
12M Excs Rtn-48.4%-31.9%-48.4%-27.2%-34.0%-31.0%-33.0%
3Y Excs Rtn-96.1%-27.9%-106.8%-134.3%-132.5%-79.4%-101.4%

Comparison Analyses

Title
0How Does HAE Stack Up Against Its Peers?
1Haemonetics vs. Merit Medical Systems: With Return Forecast Of 41%, Haemonetics Is A Better Bet
2Haemonetics vs. Integra LifeSciences: With Return Forecast Of 56%, Integra LifeSciences Is A Better Bet
3HAE or CNMD - With 19% Return Forecast, CNMD Probably Deserves Your Money
4Haemonetics vs. Alnylam Pharmaceuticals: With Return Forecast Of 85%, Alnylam Pharmaceuticals Is A Better Bet
5Haemonetics vs. ABIOMED: With Return Forecast Of 68%, ABIOMED Is A Better Bet
6Haemonetics vs. Paycom Software: With Return Forecast Of 92%, Paycom Software Is A Better Bet
7Haemonetics vs. Kulicke and Soffa Industries: Similar Market Cap, Similar Bets
8Haemonetics vs. Installed Building Products: Similar Market Cap, But Installed Building Products Is A Better Bet
9Haemonetics vs Allete: Similar Market Cap; Which Stock Is A Better Bet?

Financials

$ Mil | FY: 3/292026Q12025Q42025Q32025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q32023Q2
Period End6/28/20253/29/202512/28/20249/28/20246/29/20243/30/202412/30/20239/30/20237/1/20234/1/202312/31/202210/1/2022
Filing Date8/7/20255/21/20252/6/202511/7/20248/8/20245/20/20242/8/202411/2/20238/8/20235/22/20232/7/202311/8/2022
Key Financials Quarterly            
Total Revenue321331349346336343336318311304305297
Ebitda8310088816958705877596770
Operating Income545159524038463554354347
Net Income345837343820312541293333
EPS0.711.180.750.660.750.400.620.490.810.580.650.65
Key Financials TTM            
Total Revenue TTM1,3461,3611,3741,3611,3341,3091,2701,2391,2191,1691,1291,084
Ebitda TTM351337295277254262264261273249234227
Operating Income TTM215201189176159173170167179156140132
Net Income TTM1631681301241151181271281371159686
Growth Rates Quarterly            
Total Revenue Growth-4.4%-3.7%3.7%8.6%8.0%12.8%10.1%7.0%19.1%14.9%17.5%24.0%
EBITDA Growth19.9%72.9%26.7%38.8%-10.2%-2.6%4.0%-16.9%44.1%34.3%11.4%46.0%
Operating Income Growth35.5%32.2%28.4%46.4%-25.9%10.0%6.2%-24.5%74.4%81.6%21.4%90.7%
Net Income Growth-11.3%184.7%20.0%35.8%-6.5%-30.7%-5.2%-25.0%106.5%201.6%41.8%123.5%
Margins Quarterly            
EBITDA Margin25.7%30.1%25.3%23.4%20.5%16.8%20.7%18.3%24.6%19.4%21.9%23.6%
Operating Income Margin16.8%15.3%16.9%15.0%11.8%11.2%13.7%11.1%17.2%11.5%14.2%15.7%
Net Income Margin10.6%17.5%10.8%9.8%11.4%5.9%9.3%7.8%13.2%9.7%10.8%11.2%
Cash & Debt            
Total Cash293307321299344179194351286284224241
Total Debt1,2251,2251,2251,2251,224808871762765766767818
Net Debt / (Cash)932918904926879629677411479481543577
Cash Flows Quarterly            
FCF from Operations171174449-2764-19919806487
Cash Flows TTM            
FCF from Operations TTM22718212985135182197262250273261260
Returns to Shareholders Quarterly            
Dividends000000000000
Share Repurchases-0150-0-0-0-0-0-0-0-0-0-0
Return on Invested Capital (ROIC) Quarterly            
ROIC11.1%12.0%12.5%10.9%9.3%10.9%10.2%10.8%16.1%12.0%12.3%13.7%
Return on Invested Capital (ROIC) TTM            
ROIC TTM11.5%11.5%10.5%9.5%8.9%10.9%10.4%13.5%13.7%12.1%9.9%9.1%

Price Behavior

HAE Betas & Captures as of 8/31/2025

 1M2M3M6M1Y3Y
Beta0.911.141.070.750.740.73
Up Beta2.521.541.240.920.820.71
Down Beta-6.14-3.75-1.870.180.320.53
Up Capture14%52%80%70%61%37%
Bmk +ve Days10223571142415
Stock +ve Days8183262117382
Down Capture561%506%326%117%112%99%
Bmk -ve Days11192754106334
Stock -ve Days12222861129365

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date8292025
Short Interest: Shares Quantity3,667,472
Short Interest: % Change Since 8152025-16.1%
Average Daily Volume961,752
Days-to-Cover Short Interest3.81
Basic Shares Quantity48,111,000
Short % of Basic Shares7.6%

Returns Analyses

Earnings Returns History

Expand for More

 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
8/7/2025-26.6%-28.9%-28.2%
5/8/20255.9%6.8%9.7%
2/6/2025-11.6%-13.9%-3.6%
11/7/202410.7%17.4%3.9%
8/8/2024-10.8%-14.6%-14.6%
5/9/2024-0.7%3.5%-8.2%
2/8/20241.3%-7.6%3.2%
11/2/2023-1.1%-0.3%-2.5%
...
SUMMARY STATS   
# Positive131213
# Negative101110
Median Positive7.3%7.3%6.3%
Median Negative-8.8%-7.0%-7.4%
Max Positive16.2%23.8%33.1%
Max Negative-26.6%-28.9%-28.2%

SEC Filings

Expand for More

Report DateFiling DateFiling
6302025807202510-Q 6/28/2025
3312025521202510-K 3/29/2025
12312024206202510-Q 12/28/2024
93020241107202410-Q 9/28/2024
6302024808202410-Q 6/29/2024
3312024520202410-K 3/30/2024
12312023208202410-Q 12/30/2023
93020231102202310-Q 9/30/2023
6302023808202310-Q 7/1/2023
3312023522202310-K 4/1/2023
12312022207202310-Q 12/31/2022
93020221108202210-Q 10/1/2022
6302022810202210-Q 7/2/2022
3312022525202210-K 4/2/2022
12312021208202210-Q 1/1/2022
93020211109202110-Q 10/2/2021

Insider Activity

Expand for More

 

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.